政大機構典藏-National Chengchi University Institutional Repository(NCCUR):Item 140.119/146909
English  |  正體中文  |  简体中文  |  Post-Print筆數 : 27 |  Items with full text/Total items : 111321/142230 (78%)
Visitors : 48405072      Online Users : 959
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version
    政大典藏 > College of Commerce > MBA Program > Theses >  Item 140.119/146909


    Please use this identifier to cite or link to this item: https://nccur.lib.nccu.edu.tw/handle/140.119/146909


    Title: 新創生技製藥公司商業模式探討
    The Business Model of A New Startup Bio-Pharmaceutical Company
    Authors: 劉士彰
    Liu, Shih-Chang
    Contributors: 郭更生
    Kuo, Geng-Sheng
    劉士彰
    Liu, Shih-Chang
    Keywords: 生技製藥產業
    新創公司
    商業模式
    專業藥廠
    bio-pharmaceutical industry
    start-up company
    business model
    specialty pharmaceutical company
    Date: 2006
    Issue Date: 2023-09-01 14:58:37 (UTC+8)
    Abstract: 專業藥廠在 1990 年代中期逐漸嶄露頭角，近年來吸引了投資者的高度關注。與傳統完全整合型製藥公司 (FIPCOs) 專注於開發年銷售額超過十億美元的暢銷藥物，並投入大量研發資金開發新藥的商業模式不同; 專業藥廠採取獨特的商業模式。新創專業藥廠通常選擇經由授權/併購即將上市或已上市新藥，以免除投入新藥研發前期之高失敗風險與高成本。現已成立之專業藥廠通常主要專注於開發藥物新劑型、新藥上市前臨床研究和/或銷售與行銷。目前已成功新創之專業藥廠通常僅專注於一個或兩個專業領域，並出現了「不作研究只作開發」(NRDO) 的公司，這使他們能專注於發揮核心競爭力，降低風險和降低資本支出。

    本論文旨在探討現已能成功新創之專業藥廠的商業模式，並為未來專業生技製藥初創公司提出一個創新的商業模式。本研究提供了證據，證明該創新商業模式和策略的可行性。基於資訊科技能力和評價產品實際價值的能力作為核心競爭力，可供構建新創專業藥廠之獨特商業模式。
    Specialty pharmaceutical firms emerged in the mid-1990s, swiftly attracting investor interest. In contrast to fully integrated pharmaceutical companies (FIPCOs) pursuing blockbuster drugs through extensive R&D investment, specialty firms take a different path. They mitigate the risks and costs of earlystage molecule discovery by acquiring later-stage compounds via licensing agreements. These firms primarily focus on drug delivery, clinical development, and/or sales and marketing. Often, their emphasis lies in one or two of these areas, with instances of ”no research, development only (NRDO)” firms leveraging core competencies to reduce risks and capital expenditure.

    This thesis analyzes the business model of specialty pharmaceutical companies and proposes an innovative model for emerging specialty bio-pharmaceutical startups. The study provides compelling evidence supporting the viability of the company’s business model and strategic approaches.
    Reference: 1.林紹凱(2001)，實質選擇權評價模式於生化製藥業之應用，國立台灣大學國際企業學研究所碩士論文。
    2.劉力仁(2003)，生技製藥業評價適用性之研究-以台灣上市（櫃）公司為例，私立中原大學企業管理系碩士論文。
    3.葉姿吟(2005)，生技製藥產業鑑價模式之研究:實質選擇權之應用，國立台灣大學國際企業學研究所碩士論文。
    4.梁水金(2001)，建立一個Web-based資料挖掘系統提供藥物交互作用資訊查詢，逢甲大學資訊工程學系碩士論文。
    5.專業藥廠經營模式分析(2005)，財團法人生物技術開發中心出版。
    6.司徒達賢(2001)，策略管理新論：觀念架構與分析方法，智勝出版社。
    7.陳松男(2005)，金融工程學:金融商品創新選擇權理論。
    8.Danzon, P. M., S. Nicholson1, N. S. Pereira (2005), Productivity in pharmaceutical biotechnology R&D: the role of experience and alliances. Journal of Health Economics 24:317–339.
    9.Applegate, L. M, R. D. Austin and FW (2002), Corporate Information Strategy and Management, Text and Cases 6th ed.
    10.Bartlett, C. A. and S. Ghoshal (2000), Going Global-Lessons from Late Movers, Harvard Business Review, March-April 132-142.
    11.Neville, D. A. (2004), Specialty pharma models, Drug Delivery Technology 4(6) 2-4.
    12.Neville, D. A. (2005), Specialty pharmaceutical companies & their role within the industry, SpecialtyPharma 1(1) 18-23.
    13.Borissiouk, O. and Peli, J. (2002), Real option approach to R&D project valuation: case study at Serono, International S.A. University of Lausanne, working paper.
    14.The Boston Consult Group (2004), Rising to the productivity challenge-a strategic framework for biopharma, BCG report.
    15.Holland, S. and B. Bátiz-Lazo (2004), The global pharmaceutical industry.
    16.IBM Business Consulting Services (2004), Pharma 2010: Silicon Reality, IBM.
    17.Big Pharma Business Models Are Evolving
    18.FDA Electronic Orange Book, IMS Health and Bernstein analysis.
    19.Chang, Morris (2005), “Chang on innovation, business models, and business model innovation” speech.
    Description: 碩士
    國立政治大學
    企業管理研究所(MBA學位學程)
    93355068
    Source URI: http://thesis.lib.nccu.edu.tw/record/#G0093355068
    Data Type: thesis
    Appears in Collections:[MBA Program] Theses

    Files in This Item:

    File Description SizeFormat
    506801.pdf9955KbAdobe PDF264View/Open


    All items in 政大典藏 are protected by copyright, with all rights reserved.


    社群 sharing

    著作權政策宣告 Copyright Announcement
    1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
    The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.

    2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
    NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback